Univest
Univest
  • Markets

Is TTK Healthcare the Best Stock in Its Sector? A Look at the Numbers

  • October 9, 2026
  • Posted by: Kunal Singla
  • Category: Market
No Comments
Is TTK Healthcare the Best Stock in Its Sector? A Look at the Numbers

TTK Healthcare CMP Rs 1,004 (09 Oct 2026). Market cap Rs 1,426 Cr. ROE 5.89%. P/E 19.28x versus Industry P/E 23.61x.

Quick Answer

TTK Healthcare is one of the names investors compare when screening the Healthcare sector, built on a 5.89% return on equity and a P/E of 19.28x against an Industry P/E of 23.61x. Whether TTK Healthcare is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.

Is TTK Healthcare the best stock in its sector? The stock trades on the NSE at Rs 1,004 as of 09 October 2026, within its 52-week range of Rs 735.00 to Rs 1,247.00. TTK Healthcare Ltd sells consumer products such as Woodward’s Gripe Water, Eva, Good Home and Skore, which account for about 31 percent of revenue.

TTK Healthcare sits in the Healthcare sector, and its 5.89% ROE and 19.28x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • About TTK Healthcare
  • Is TTK Healthcare the Best Stock in Its Sector?
  • How TTK Healthcare Compares Against Its Healthcare Sector Peers
  • What Makes TTK Healthcare Worth Watching in Healthcare
  • TTK Healthcare Valuation: Is It Justified?
  • How to Track TTK Healthcare Before You Invest
  • Conclusion
    • Is TTK Healthcare the best stock in its sector?
    • What is the current share price of TTK Healthcare?
    • What sector does TTK Healthcare belong to?
    • How does TTK Healthcare compare to its sector peers on P/E?
    • What is TTK Healthcare’s return on equity?
    • Should I invest in TTK Healthcare based on its sector position?

About TTK Healthcare

TTK Healthcare Ltd sells consumer products such as Woodward’s Gripe Water, Eva, Good Home and Skore, which account for about 31 percent of revenue. Promoter T T Jagannathan passed away on 9 October 2025, a leadership change investors have followed. The stock trades about 19 percent below its 52-week high and about 37 percent above its 52-week low. At a market capitalisation of Rs 1,426 Cr, it is tracked as part of the Healthcare sector on Univest.

Is TTK Healthcare the Best Stock in Its Sector?

TTK Healthcare’s case rests on valuation and balance sheet strength rather than returns. TTK Healthcare’s 19.28x P/E is below the 23.61x Industry P/E and debt is negligible at 0.02, but a 5.89% ROE is low, so the stock looks reasonable on the earnings multiple rather than on returns.

Metric TTK Healthcare
CMP (NSE) Rs 1,004.40
52-Week High / Low Rs 1,247.00 / Rs 735.00
Market Cap Rs 1,426 Cr
P/E (TTM) vs Industry P/E 19.28x vs 23.61x
P/B 1.28
ROE 5.89%
EPS (TTM) Rs 52.34
Dividend Yield 0.99%
Debt to Equity 0.02

Compare TTK Healthcare Against Other Healthcare Sector Stocks

How TTK Healthcare Compares Against Its Healthcare Sector Peers

The table below sets TTK Healthcare against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company Market Cap (Rs Cr) P/E ROE Debt to Equity
TTK Healthcare 1,426 19.28 5.89% 0.02
Amrutanjan Health Care 1,458 27.01 17.42% 0.00
FDC 5,281 18.05 11.32% 0.01
Peer average (2 companies) – 22.53 14.37% 0.01

Against this peer set, TTK Healthcare’s 5.89% ROE is below the 14.37% peer average, and its P/E of 19.28x runs below the peer average of 22.53x. TTK Healthcare’s 19.28x P/E is below the 23.61x Industry P/E and debt is negligible at 0.02, but a 5.89% ROE is low, so the stock looks reasonable on the earnings multiple rather than on returns.

What Makes TTK Healthcare Worth Watching in Healthcare

  • Debt free balance sheet: A debt to equity ratio of 0.02 means interest costs barely touch earnings.
  • Recognised brands: Woodward’s Gripe Water, Eva, Good Home and Skore give the consumer products arm brand recall.
  • Low ROE: A 5.89% ROE is the main weakness against a modest valuation discount.

TTK Healthcare Valuation: Is It Justified?

TTK Healthcare’s 19.28x P/E is below the 23.61x Industry P/E and debt is negligible at 0.02, but a 5.89% ROE is low, so the stock looks reasonable on the earnings multiple rather than on returns. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Total Transport Systems the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track TTK Healthcare and other Healthcare sector stocks.

How to Track TTK Healthcare Before You Invest

Before deciding whether TTK Healthcare deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

  1. Open the Univest Screener and search for TTK Healthcare to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
  2. Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
  3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
  4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

TTK Healthcare is worth researching mainly on valuation, with a P/E of 19.28x against a 23.61x Industry P/E, but a 5.89% ROE is modest, so the case for calling it the best stock in its sector rests on more than current returns. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Is TTK Healthcare the best stock in its sector?

Ans. TTK Healthcare has a 5.89% ROE and trades at 19.28x P/E against a 23.61x Industry P/E, and compares below the peer average ROE of 14.37% in this article’s named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of TTK Healthcare?

Ans. TTK Healthcare was trading at Rs 1,004.40 on the NSE as of 09 October 2026, within its 52-week range of Rs 735.00 to Rs 1,247.00.

What sector does TTK Healthcare belong to?

Ans. TTK Healthcare is classified under the Healthcare sector on Univest.

How does TTK Healthcare compare to its sector peers on P/E?

Ans. TTK Healthcare’s P/E of 19.28x is below the 22.53x average of the 2 named peers compared in this article.

What is TTK Healthcare’s return on equity?

Ans. TTK Healthcare reported a return on equity of 5.89%, which is below the 14.37% average of its named peers in this comparison.

Should I invest in TTK Healthcare based on its sector position?

Ans. TTK Healthcare’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.

{“@context”: “https://schema.org”, “@type”: “FAQPage”, “mainEntity”: [{“@type”: “Question”, “name”: “Is TTK Healthcare the best stock in its sector?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “TTK Healthcare has a 5.89% ROE and trades at 19.28x P/E against a 23.61x Industry P/E, and compares below the peer average ROE of 14.37% in this article’s named comparison, so the answer depends on what an investor is prioritising.”}}, {“@type”: “Question”, “name”: “What is the current share price of TTK Healthcare?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “TTK Healthcare was trading at Rs 1,004.40 on the NSE as of 09 October 2026, within its 52-week range of Rs 735.00 to Rs 1,247.00.”}}, {“@type”: “Question”, “name”: “What sector does TTK Healthcare belong to?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “TTK Healthcare is classified under the Healthcare sector on Univest.”}}, {“@type”: “Question”, “name”: “How does TTK Healthcare compare to its sector peers on P/E?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “TTK Healthcare’s P/E of 19.28x is below the 22.53x average of the 2 named peers compared in this article.”}}, {“@type”: “Question”, “name”: “What is TTK Healthcare’s return on equity?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “TTK Healthcare reported a return on equity of 5.89%, which is below the 14.37% average of its named peers in this comparison.”}}, {“@type”: “Question”, “name”: “Should I invest in TTK Healthcare based on its sector position?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “TTK Healthcare’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.”}}]}



sector stocks Stock Market
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply